

## Paediatric and Regulatory Considerations: The Proposed Changes to European Legislation

**David Carling and Kieron O'Connell** UK and European Patent Attorneys November 2023



# Topics



2

Data/Marketing Protection - Current Regime

European Commission Proposal


- 3
- European Parliament Proposal
- 4 Orphan Drugs
- 5 Paediatric Rewards






## **C** The Proposed Regime (European Commission)





Repeal of Directives 2001/83/EC and 2009/35/EC, and incorporation of parts of Regulation (EC) No 1901/2006 (the Paediatric Regulation)

## **C** The Proposed Regime – Overview



Default minimum protection is shortened to 8 years (6 DP + 2 MP)

Data protection period can be extended:

- 1. Release and continuous supply in EU (2 years)
- 2. New indication (1 year)
- 3. Unmet medical need (1/2 year)
- 4. Clinical trial used evidence-based comparator (1/2 year)

## **C** The Proposed Regime – Release and Continuous Supply



- New product must be released and continuously supplied "in a sufficient quantity and in the presentations necessary to cover the needs of the patients"
- Supply required in all EU states in which MA is valid
- Launch must occur within 2 years of approval (3 years for SMEs)
- Application for extra 2 years submitted in 34-36 month window

## **C** The Proposed Regime – New Indication



- MA holder must receive authorisation for additional therapeutic indication "during the data protection period"
- Replaces existing "+1"
- Treatment must give significant clinical benefit in comparison with existing therapies
- incompatible with 6-month paediatric SPC extension

## The Proposed Regime – Other Data Protection Extensions



- 1. Unmet Medical Need
  - Life threatening or severely debilitating disease for which there is either no medicinal product authorised in EU or the indication is associated with high morbidity or mortality.
  - Product must achieve "meaningful reduction" in morbidity or mortality.
- 2. Clinical trial (for new API) uses evidence-based comparator

## **C** The Proposed Regime – European Parliament's Comments

	EC Proposal	EP Draft
Standard period of data + market protection [Arts. 80(2) + 81(1)]	6 + 2 years	9 + 2 years
Release and supply in sufficient quantities [Arts. 81(2)(a) + 82]	+ 2 years data protection	Deleted
Product addresses an unmet medical need [Arts. 81(2)(b) + 83]	+ 6 months data protection	+ 1 year data protection; broader definition of UMN
Comparative clinical trials conducted in accordance with EMA scientific advice [Art. 81(2)(c)]	+ 6 months data protection (only for initial applications containing a NAS)	+ 6 months data protection (for all applications)
New therapeutic indication [Art. 81(2)(d)]	+ 1 year data protection (available once)	+ 1 year data protection (available once)







Repeal and replacement of Regulation (EC) No 141/2000 (the Orphan Regulation) Repeal and incorporation of Regulation (EC) No 1901/2006 (the Paediatric Regulation)

## **C** The Proposed Regime – Orphan Drugs – Overview



- **+1 year** if product addresses "high unmet medical need":
  - either no medicinal product is authorised in EU, or the approved product will bring "exceptional therapeutic advancement";
  - product must achieve "meaningful" reduction in morbidity or mortality.
- +1 year for new indications of orphan medicinal products (max 2)
- **+1 year** if product is launched in all EU member states

MS

# **Orphan Drugs – European Parliament's Comments**

	EC Proposal	EP Draft
Standard orphan market exclusivity [Art. 71(2)(a)]	9 years	8 years
Products addressing a high unmet medical need (HUMN) [Art. 71(2)(b)]	10 years	<b>10 years</b> (HUMN defined more narrowly)
New orphan therapeutic indication [Art. 71(2)(ba)]	Not specified	5 years
Orphan products with MA based on bibliographic data [Art. 71(2)(c)]	5 years	3 years
Release and supply in sufficient quantities in relevant MS [Art. 72(1)]	+ 1 year	Deleted
New indication for a different orphan condition [Art. 72(2)]	+ 1 year (if indication obtained >2 years before the end of exclusivity period)	+1 year (if indication obtained >3 years before the end of exclusivity period)



- New category for data protection
- 4 years of data protection [Art. 84]
- Available once and in narrow circumstances:
- Approved drug must provide a significant clinical benefit, and
  - there has been no prior data protection in the EU, or
  - first marketing approval in EU occurred
    >25 years ago



### **Bolar Exemption - Proposed Changes**

#### **European Commission's Proposal [Art. 85]**

The Commission's proposal **extends** the Bolar exemption scope and clarify some uncertainties

The following acts would not be considered as infringing acts:

- a) studies, trials and other activities conducted to generate data for an application for:
  - a marketing authorisation of generic, biosimilar, hybrid or bio-hybrid medicinal products and for subsequent variations; health technology assessment as defined in Regulation (EU) i.
  - ii. 2021/2282;
  - iii. pricing and reimbursement.
- the activities conducted exclusively for the purposes set out in point (a), may cover the submission of the application for a marketing authorisation and the offer, manufacture, sale, supply, storage, import, use and purchase of patented medicinal products or processes, including by third party b) suppliers and service providers.

This exception shall not cover the placing on the market of the medicinal products resulting from such activities



## **Bolar Exemption - Proposed Changes**

#### **European Parliament's Draft Report**

The Commission's proposal **extends** the Bolar exemption scope and clarify some uncertainties

The following acts would not be considered as infringing acts:

- *a) studies, trials and other activities conducted to generate data for an application for:* 
  - *i.* a marketing authorisation of generic, biosimilar, hybrid or biohybrid medicinal products and for subsequent variations;
  - *hybrid medicinal products and for subsequent variations; ii. health technology assessment as defined in Regulation (EU)* 2021/2282;
  - iii. pricing and reimbursement.
- b) the activities conducted exclusively for the purposes set out in point (a), may cover the submission of the application for a marketing authorisation and the offer, manufacture, sale, supply, storage, import, use and purchase of patented medicinal products or processes, including by third party suppliers and service providers.

This exception shall not cover the placing on the market of the medicinal products resulting from such activities





### **Paediatric Rewards**

## **Paediatric Rewards – The Current Regime**

- In the EU, paediatric rewards are governed by Regulation (EC) No. 1901/2006 ('the Paediatric Regulation')
  - Six-month extension to SPC term available if application for MA/subsequent request for variation includes results from agreed PIP (Art 36(1)), and drug is authorised in all EU member states (Art 36(2))
  - Not available if:
    - Drug has orphan status (Art. 36(4))
    - +1 year of marketing protection obtained for the paediatric indication (Art. 36(5))
  - Possibility to obtain 2-year extension to 10-year orphan designation market exclusivity (Art. 37)
  - Off-patent products approved by paediatric use marketing authorisation entitled to 8+2 years exclusivity (Art. 38)

## **Paediatric Rewards and orphan designation**

- Orphan drug status precludes the possibility of obtaining a paediatric extension (Art. 36(4) Paediatric Regulation).
- However, if orphan status is revoked before paediatric studies are complete, a paediatric extension is likely to be available
  - Novartis v Mylan, District Court of The Hague, 2020<sup>1</sup>
    - Novartis obtained paediatric extension of deferasirox (Exjade®), which was previously designated as an orphan drug.
    - Court held that as orphan market exclusivity had expired when paediatric studies were completed, there was no double incentive for paediatric studies
    - Paediatric extension therefore valid
- Expected that this approach will be followed by Courts in other countries



## **Paediatric extensions in Switzerland**

- Available since 2019
- Requirements mirror those in EU Application for Swiss MA must include the results of studies performed in accordance with agreed PIP (which must be certified by Swissmedic)
- Application for Swiss MA (or the relevant extension to the MA) must be made not more than six months from the relevant MA application in Europe
  - Swiss attorneys have advised that this deadline is triggered by the first MA application *containing a PIP*, rather than the results of the PIP.
  - Best practice to mirror EU regulatory steps in Switzerland within 6 months
- During transition period (1 January 2019-31 December 2023) deadline is 6 months before expiry of the SPC. From 1 January 2024, deadline will match EU deadline (2 years before SPC expiry).
- Paediatric SPC (6-month extension to patent term) also available





- From 1 January 2021, UK Human Medicines Regulations (2012) replaced EU legislation
- Deadlines are the same as in the EU (applications must be filed 2 years before SPC expiry).
- MHRA statement of compliance required (for GB)
- No requirement that medicinal product is authorised in all member states



#### Proposed changes to Paediatric Rewards in Europe

The European Commission's Proposals

- The EC's proposed regulation would repeal the Paediatric Regulation, with relevant parts incorporated into the new Regulation and Directive.
- Rewards for paediatric medicinal products described in Art. 86 of the Proposed Directive.
  - 6-month paediatric extension (Art. 86(1))
  - Prohibition on paediatric extension and `+1' year data exclusivity being granted for the same paediatric indication (Art. 86(4))
  - +2 years orphan exclusivity for completion of PIP removed
  - Prohibition on paediatric extension for orphan products also removed
- Products approved under PUMA entitled to (new) data and marketing protection periods (Art. 93, Proposed Regulation)

## Proposed changes to Paediatric Rewards in Europe

The Draft European Parliament Reports

- The draft European Parliament Reports do not suggest many changes to the European Commission's Proposals
- The Report on the Directive proposes an amendment to Art 86(1) to provide for a oneyear paediatric extension if the PIP is conducted for a different disease from the intended use in the adult population



## Thank you

## Any questions?

Potter Clarkson UK, Sweden, Denmark W potterclarkson.com | E info@potterclarkson.com